Literature DB >> 9375880

Giant cell arteritis in Lugo, Spain, is associated with low longterm mortality.

M A González-Gay1, R Blanco, V Abraira, C García-Porrúa, D Ibáñez, M J García-Pais, M T Rigueiro, A Sánchez-Andrade, J Guerrero, E Casariego.   

Abstract

OBJECTIVE: To assess the longterm survival of patients with giant cell arteritis (GCA) in a well defined area in Northwestern Spain.
METHODS: A followup study of consecutive biopsy proven patients with GCA diagnosed in Lugo, Spain January 1, 1982-March 31, 1996 was performed. Patients were followed from time of diagnosis until either their death or October 1, 1996. Time and cause of death were reviewed. Statistical methods included standardized mortality ratio (SMR), and Kaplan-Meier product-limit survival analysis. Cox proportional hazard models were used to identify clinical features and laboratory findings associated with survival.
RESULTS: By October 1, 1996, full information about 109 biopsy proven patients with GCA (59 men/50 women) was available. The mean age +/- SD at the time of diagnosis was 73.9 +/- 7.3 years for women and 74.1 +/- 5.8 for men (p = NS). After a median followup of 54 months, 22 patients (20.2%) had died. Three died within the first month after diagnosis due to either vascular complications related to GCA or therapy complications. Apart from a history of severe underlying diseases (comorbid condition unrelated to GCA), neither sex nor any clinical features of GCA were significantly associated with an increase in mortality. As in the general population of the same age in Lugo, the majority of deaths were due to cardiovascular and cerebrovascular complications. SMR was 0.80 (95% CI 0.47-1.13). One, 2, 5, and 10 year survival rates were 95, 91, 81, and 62%, respectively. Hazard function was 1.8% at Day 30 after diagnosis and remained low until the end of the first year of treatment. Thereafter, mortality increased slightly. As this function was constant, we applied an exponential model. The estimated risk of death with this model was 5.3% per year.
CONCLUSION: Longterm mortality of GCA in our area is low. However, it may be possible to further lower the mortality rate through early diagnosis and careful followup.

Entities:  

Mesh:

Year:  1997        PMID: 9375880

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  12 in total

Review 1.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 2.  Giant cell arteritis and polymyalgia rheumatica: pathophysiology and management.

Authors:  Miguel A Gonzalez-Gay; Carlos Garcia-Porrua; Jose A Miranda-Filloy; Javier Martin
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

Review 3.  Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.

Authors:  Jean Schmidt; Kenneth J Warrington
Journal:  Drugs Aging       Date:  2011-08-01       Impact factor: 3.923

Review 4.  Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions.

Authors:  Justin C Mason; Peter Libby
Journal:  Eur Heart J       Date:  2014-11-27       Impact factor: 29.983

5.  Healthcare Use and Direct Cost of Giant Cell Arteritis: A Population-based Study.

Authors:  Matthew J Koster; Sara J Achenbach; Cynthia S Crowson; Hilal Maradit-Kremers; Eric L Matteson; Kenneth J Warrington
Journal:  J Rheumatol       Date:  2017-05-01       Impact factor: 4.666

6.  Overall and cause-specific mortality in giant cell arteritis : A meta-analysis.

Authors:  Y H Lee; G G Song
Journal:  Z Rheumatol       Date:  2018-12       Impact factor: 1.372

7.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis.

Authors:  Tanaz A Kermani; Kenneth J Warrington; Cynthia S Crowson; Steven R Ytterberg; Gene G Hunder; Sherine E Gabriel; Eric L Matteson
Journal:  Ann Rheum Dis       Date:  2012-12-19       Impact factor: 19.103

8.  Giant cell arteritis and mortality.

Authors:  R Wade Crow; Bradley J Katz; Judith E A Warner; Stephen C Alder; Kang Zhang; Susan Schulman; Kathleen B Digre
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2009-02-04       Impact factor: 6.053

Review 9.  Translational mini-review series on immunology of vascular disease: accelerated atherosclerosis in vasculitis.

Authors:  J W Cohen Tervaert
Journal:  Clin Exp Immunol       Date:  2009-03-20       Impact factor: 4.330

10.  Extra- and intracranial cerebral vasculitis in giant cell arteritis: an observational study.

Authors:  Delphine Larivière; Karim Sacre; Isabelle Klein; Fabien Hyafil; Laurence Choudat; Marie-Paule Chauveheid; Thomas Papo
Journal:  Medicine (Baltimore)       Date:  2014-12       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.